The Jerusalem Post - Israel News

Panaxia

Panaxia becomes first in Europe to be approved to export cannabis solution

Inhalation of medical cannabis through a vaporizer is often regarded as a healthier form of consumption than smoking, due to the reduced damage caused to the mouth, throat and lungs.

|ByIDAN ZONSHINE
A woman exhales after vaping in Times Square, during the coronavirus disease (COVID-19) outbreak, in New York City, U.S., March 31, 2020
Medical cannabis sublingual tablets from the Naxiva-Panaxir line by Panaxia and Neuraxpharm.

Israeli medical cannabis company delivers first product to Cyprus

|ByJERUSALEM POST STAFF
Medical cannabis sublingual tablets from the Naxiva-Panaxir line by Panaxia and Neuraxpharm.

Israeli medical cannabis company selected for exclusive French pilot

Panaxia was selected as one of only four main suppliers for the pilot, along with its European partner, Neuraxpharm.

|ByIDAN ZONSHINE
Assi Rotbart, Chief Business Officer and Director at Panaxia, stands with Yuval Landschaft, the director of the Healthy Ministry's Medical Cannabis Unit alongside Israel's first commercial export of medical cannabis products to Germany.

First commercial medical cannabis export from Israel lands in Germany

Germany is home to the fastest-growing medical cannabis market outside the US.

|ByIDAN ZONSHINE

Israeli medical cannabis approved for export to Germany, France

Only last month, Panaxia became the first Israeli medical cannabis company receive a commercial export license.

DECEMBER 12, 2020ByIDAN ZONSHINE
Panaxia and Neuraxpharm's Naxiva-Panaxol brand medical cannabis oil